Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022
| Author | Pouya Safarzadeh Kozani | en |
| Author | Pooria Safarzadeh Kozani | en |
| Author | Abdolkarim Sheikhi | en |
| Orcid | Pouya Safarzadeh Kozani [0000-0002-2602-3871] | en |
| Orcid | Pooria Safarzadeh Kozani [0000-0002-9901-7851] | en |
| Orcid | Abdolkarim Sheikhi [0000-0002-3559-5548] | en |
| Issued Date | 2021-11-30 | en |
| Abstract | This article does not have an abstract. | en |
| DOI | https://doi.org/10.5812/tms.123546 | en |
| URI | https://brieflands.com/journals/jai/articles/123546 | en |
| Keyword | Tumor Immunotherapy | en |
| Keyword | TCR-scFv Fusion Protein | en |
| Keyword | gp100 | en |
| Keyword | Tebentafusp | en |
| Publisher | Brieflands | en |
| Title | Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022 | en |
| Type | Letter | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- tms-1-4-123546.pdf
- Size:
- 87.45 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF